S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Bangladesh seeks China help to repatriate Rohingya refugees
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Bangladesh seeks China help to repatriate Rohingya refugees
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Bangladesh seeks China help to repatriate Rohingya refugees
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Bangladesh seeks China help to repatriate Rohingya refugees
NASDAQ:TMDX

TransMedics Group - TMDX Stock Forecast, Price & News

$48.78
+7.57 (+18.37%)
(As of 08/5/2022 08:49 PM ET)
Add
Compare
Today's Range
$42.20
$48.90
50-Day Range
$25.73
$48.78
52-Week Range
$10.00
$48.90
Volume
2.40 million shs
Average Volume
280,083 shs
Market Capitalization
$1.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.00

TransMedics Group MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
5.7% Downside
$46.00 Price Target
Short Interest
Healthy
5.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.01mentions of TransMedics Group in the last 14 days
Based on 36 Articles This Week
Insider Trading
Selling Shares
$5.63 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.57) to ($0.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

902nd out of 1,283 stocks

Electromedical Equipment Industry

22nd out of 29 stocks

TMDX stock logo

About TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Wall Street Analyst Weigh In

Several research firms have weighed in on TMDX. JPMorgan Chase & Co. raised TransMedics Group from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $26.00 to $48.00 in a research report on Tuesday, August 2nd. Canaccord Genuity Group raised their price target on TransMedics Group from $46.00 to $58.00 in a research report on Thursday. Cowen raised their price target on TransMedics Group from $45.00 to $50.00 in a research report on Tuesday, August 2nd. Morgan Stanley raised their price target on TransMedics Group from $34.00 to $37.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 3rd. Finally, Cowen raised their price objective on TransMedics Group from $39.00 to $45.00 and gave the stock an "outperform" rating in a report on Tuesday, July 26th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $46.00.

TransMedics Group Price Performance

Shares of TransMedics Group stock opened at $48.78 on Monday. TransMedics Group has a twelve month low of $10.00 and a twelve month high of $48.90. The stock has a market capitalization of $1.36 billion, a P/E ratio of -28.36 and a beta of 1.63. The company has a current ratio of 5.22, a quick ratio of 4.40 and a debt-to-equity ratio of 0.59. The business's fifty day moving average price is $32.37 and its 200 day moving average price is $25.28.

TransMedics Group (NASDAQ:TMDX - Get Rating) last issued its earnings results on Monday, August 1st. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.09). TransMedics Group had a negative net margin of 92.76% and a negative return on equity of 69.38%. During the same period last year, the firm posted ($0.39) earnings per share. As a group, research analysts anticipate that TransMedics Group will post -1.57 earnings per share for the current year.

Insiders Place Their Bets

In other TransMedics Group news, CFO Stephen Gordon sold 10,000 shares of the business's stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $35.00, for a total transaction of $350,000.00. Following the transaction, the chief financial officer now owns 5,714 shares in the company, valued at $199,990. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Tamer I. Khayal sold 13,504 shares of TransMedics Group stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $40.01, for a total transaction of $540,295.04. Following the sale, the insider now directly owns 46,076 shares of the company's stock, valued at $1,843,500.76. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Stephen Gordon sold 10,000 shares of TransMedics Group stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $35.00, for a total value of $350,000.00. Following the sale, the chief financial officer now directly owns 5,714 shares in the company, valued at $199,990. The disclosure for this sale can be found here. Insiders have sold a total of 151,814 shares of company stock worth $5,633,336 over the last quarter. 8.70% of the stock is owned by corporate insiders.

Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

TMDX Stock News Headlines

TransMedics Group (NASDAQ:TMDX) PT Raised to $58.00
TransMedics Group (TMDX) Scheduled to Post Earnings on Monday
4 Analysts Have This to Say About TransMedics Group
Analyst Ratings for TransMedics Group
See More Headlines
Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

TMDX Company Calendar

Last Earnings
8/01/2022
Today
8/08/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TMDX
Fax
N/A
Employees
148
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.00
High Stock Price Forecast
$58.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
-5.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-44,220,000.00
Pretax Margin
-119.78%

Debt

Sales & Book Value

Annual Sales
$30.26 million
Book Value
$2.44 per share

Miscellaneous

Free Float
25,650,000
Market Cap
$1.36 billion
Optionable
Not Optionable
Beta
1.63














TMDX Stock - Frequently Asked Questions

Should I buy or sell TransMedics Group stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TransMedics Group stock.
View analyst ratings for TransMedics Group
or view top-rated stocks.

What is TransMedics Group's stock price forecast for 2022?

7 equities research analysts have issued 12-month price objectives for TransMedics Group's shares. Their TMDX stock forecasts range from $37.00 to $58.00. On average, they anticipate TransMedics Group's stock price to reach $46.00 in the next twelve months. This suggests that the stock has a possible downside of 5.7%.
View analysts' price targets for TransMedics Group
or view top-rated stocks among Wall Street analysts.

How has TransMedics Group's stock performed in 2022?

TransMedics Group's stock was trading at $19.16 on January 1st, 2022. Since then, TMDX stock has increased by 154.6% and is now trading at $48.78.
View the best growth stocks for 2022 here
.

When is TransMedics Group's next earnings date?

TransMedics Group is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our earnings forecast for TransMedics Group
.

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) posted its earnings results on Monday, August, 1st. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.32) by $0.09. TransMedics Group had a negative net margin of 92.76% and a negative trailing twelve-month return on equity of 69.38%. During the same quarter last year, the business posted ($0.39) EPS.

What guidance has TransMedics Group issued on next quarter's earnings?

TransMedics Group issued an update on its FY 2022 earnings guidance on Tuesday, August, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $67.00 million-$75.00 million, compared to the consensus revenue estimate of $66.97 million.

What is Waleed Hassanein's approval rating as TransMedics Group's CEO?

17 employees have rated TransMedics Group CEO Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among TransMedics Group's employees.

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).

When did TransMedics Group IPO?

(TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Emerald Advisers LLC (1.42%), Emerald Mutual Fund Advisers Trust (1.24%), Royce & Associates LP (0.51%), Moody Aldrich Partners LLC (0.38%), Lisanti Capital Growth LLC (0.38%) and Envestnet Asset Management Inc. (0.20%). Company insiders that own TransMedics Group stock include Abrams Capital Management, LP, David Weill, Edwin M Kania Jr, James R Tobin, John F Carey, John F Carey, John F Sullivan, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein.
View institutional ownership trends for TransMedics Group
.

How do I buy shares of TransMedics Group?

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $48.78.

How much money does TransMedics Group make?

TransMedics Group (NASDAQ:TMDX) has a market capitalization of $1.37 billion and generates $30.26 million in revenue each year. The company earns $-44,220,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis.

How many employees does TransMedics Group have?

TransMedics Group employs 148 workers across the globe.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The official website for TransMedics Group is www.transmedics.com. The company can be reached via phone at (978) 552-0900 or via email at investors@transmedics.com.

This page (NASDAQ:TMDX) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.